Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study.
|Abstract||The effect of resolving metabolic syndrome on target organ damage in hypertensive patients is not well described. We evaluated whether treating metabolic syndrome (MetS) with an angiotensin receptor blocker subsequently reduced microalbuminuria in the K-MetS cohort.|
A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
|Journal Title||plos one|
|Publication Year Start||2018-01-01|
PMID- 29261715 OWN - NLM STAT- MEDLINE DCOM- 20180108 LR - 20180108 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 12 DP - 2017 TI - Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study. PG - e0189342 LID - 10.1371/journal.pone.0189342 [doi] AB - BACKGROUND: The effect of resolving metabolic syndrome on target organ damage in hypertensive patients is not well described. We evaluated whether treating metabolic syndrome (MetS) with an angiotensin receptor blocker subsequently reduced microalbuminuria in the K-MetS cohort. METHODS: Among 10,601 total metabolic syndrome patients, 3,250 (52.2% male, 56.2+/-10.0 years) with sufficient data on five specific metabolic components were included in this study. Patients were divided into four groups based on MetS status at baseline and 3 months. All patients received an angiotensin receptor blocker, fimasartan, for these 3 months; thereafter, treatment was modified at the discretion of each patient's physician. Microalbuminuria and the albumin/creatine ratio were evaluated as a proxy of organ damage. RESULTS: Blood pressure and waist circumference decreased from baseline to 3 months and 1 year. The average albumin/creatinine ratio significantly improved during the first three months of the study from 36.0+/-147.4 to 21.0+/-74.9 mg/g (p<0.05) and was persistently high in patients with MetS at baseline and 3 months versus other groups. Women in comparison with men showed significantly lower ACR among patients with newly developed MetS at 3-month. CONCLUSIONS: Treatment of hypertensive patients for one year with the angiotensin receptor blocker fimasartan significantly reduced the albumin/creatine ratio, irrespective of whether the patient had MetS; however, the albumin/creatinine ratio was significantly higher in patents with persistent or newly developed MetS compared to patients without MetS. Additionally, these findings were more prominent in women than in men. FAU - Park, Jeong Bae AU - Park JB AUID- ORCID: http://orcid.org/0000-0002-5623-7010 AD - JB lab and clinic, Seoul, South Korea. AD - Department of Medicine, Cheil General Hospital, Dankook University College of Medicine, Seoul, South Korea. FAU - Kim, Su-A AU - Kim SA AD - Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Sung, Ki-Chul AU - Sung KC AD - Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Kim, Jang Young AU - Kim JY AD - Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Gangwon-do, Republic of Korea. LA - eng PT - Journal Article DEP - 20171219 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Albumins) RN - 0 (Biphenyl Compounds) RN - 0 (Pyrimidines) RN - 0 (Tetrazoles) RN - AYI8EX34EU (Creatinine) RN - P58222188P (fimasartan) SB - IM MH - Albumins/metabolism MH - Albuminuria/*drug therapy/*epidemiology/physiopathology MH - Biphenyl Compounds/*therapeutic use MH - Blood Pressure MH - Creatinine/metabolism MH - Female MH - Humans MH - Incidence MH - Male MH - Metabolic Syndrome/*drug therapy/*epidemiology/physiopathology MH - Middle Aged MH - Pyrimidines/*therapeutic use MH - *Sex Characteristics MH - Sex Factors MH - Tetrazoles/*therapeutic use PMC - PMC5736217 EDAT- 2017/12/21 06:00 MHDA- 2018/01/09 06:00 CRDT- 2017/12/21 06:00 PHST- 2017/06/22 00:00 [received] PHST- 2017/11/22 00:00 [accepted] PHST- 2017/12/21 06:00 [entrez] PHST- 2017/12/21 06:00 [pubmed] PHST- 2018/01/09 06:00 [medline] AID - 10.1371/journal.pone.0189342 [doi] AID - PONE-D-17-23733 [pii] PST - epublish SO - PLoS One. 2017 Dec 19;12(12):e0189342. doi: 10.1371/journal.pone.0189342. eCollection 2017.